.png)
Cogniza 90 mg: Stroke Recovery and Brain Health Uses
Cogniza 90 mg is a prescription tablet marketed in India that contains cerebroprotein hydrolysate, a mixture of small peptides derived from porcine brain tissue. Indian drug listings describe it for neurological conditions including stroke recovery, head injury, and Alzheimer’s disease, usually as part of a broader treatment plan rather than as stand-alone therapy. The proposed idea is that these peptides may support nerve-cell survival and neurological recovery, but the quality of clinical evidence varies considerably. Importantly, much of the published research concerns injectable peptide preparations such as Cerebrolysin—not the Cogniza 90 mg oral tablet itself—so those results cannot automatically be transferred to this product. Modern stroke recovery still depends heavily on rehabilitation, prevention of another stroke, and treatment of complications and risk factors. This guide explains Cogniza 90 mg uses, its possible role after stroke, the limits of current evidence, and important safety points.
What Is Cogniza 90 mg Tablet?
Cogniza 90 mg is an oral prescription medicine containing cerebroprotein hydrolysate. Current Indian listings identify Linux Laboratories as the marketer/manufacturer and list 90 mg of cerebroprotein hydrolysate per tablet.
The Cogniza drug information in CIMS India describes Cogniza 90 mg tablets as containing a porcine brain-derived peptide preparation.
Cerebroprotein hydrolysate is intended to provide low-molecular-weight peptides and amino-acid components that may have neurotrophic or neuroprotective activity. These terms broadly mean supporting nerve-cel l function, survival, or repair processes.
That proposed mechanism should not be confused with a guaranteed clinical benefit. Demonstrating biological activity in laboratory or experimental settings is different from proving that an oral tablet improves disability, memory, independence, or long-term stroke outcomes in people.
Cogniza 90 mg Medication Information at a Glance
Medication detail | Information |
Brand | Cogniza 90 mg Tablet |
Listed active ingredient | Cerebroprotein hydrolysate 90 mg |
Source described by CIMS India | Porcine brain-derived peptide |
Route | Oral tablet |
Prescription status | Prescription medicine in current Indian pharmacy listings |
Conditions commonly listed | Stroke, head injury, and Alzheimer’s disease |
Dose and duration | Should be determined by the treating doctor |
Role in stroke care | May be prescribed as supportive therapy; it does not replace established stroke treatment or rehabilitation |
Evidence limitation | High-quality direct evidence specifically for the Cogniza 90 mg oral formulation is limited |
How May Cogniza 90 mg Be Used During Stroke Recovery?
Cogniza 90 mg may be prescribed as supportive neurological therapy after a stroke, but it should not be viewed as the main treatment responsible for recovery. Stroke rehabilitation involves rebuilding function through structured physical, occupational, speech, cognitive, and other therapies according to the problems caused by the stroke.
The 2026 AHA/ASA stroke rehabilitation guideline emphasizes that multidisciplinary rehabilitation is critical for reducing neurological impairment and improving function after stroke. Rehabilitation should begin during the acute phase when medically appropriate and continue according to an individual’s changing needs.
Depending on the part of the brain affected, rehabilitation may address:
Weakness or difficulty walking.
Poor balance and coordination.
Difficulty using an arm or hand.
Problems speaking or understanding language.
Difficulty swallowing.
Problems with memory, attention, or planning.
Changes in mood and emotional health.
Difficulty returning to everyday activities.
A medicine marketed for neurological recovery should therefore be understood as only one possible component of care. It cannot replace physiotherapy, occupational therapy, speech therapy, appropriate exercise, blood-pressure management, cholesterol treatment, diabetes management, antiplatelet or anticoagulant treatment when indicated, and other strategies used to prevent another stroke.
After a stroke, improvement should not be attributed to one tablet alone. Recovery reflects the brain injury itself, natural healing, rehabilitation intensity, prevention of complications, control of stroke risk factors, and any medicines prescribed as part of the overall treatment plan.
What Does the Evidence Say About Cerebroprotein Hydrolysate and Stroke?
The evidence is uncertain, particularly when trying to apply research on other peptide preparations to Cogniza 90 mg tablets. High-quality evidence directly demonstrating that the oral Cogniza formulation improves long-term independence after stroke is limited.
One important distinction is between Cogniza and Cerebrolysin. Both are described as brain-derived peptide preparations, but Cerebrolysin has mainly been studied as an injectable product. Results from injectable Cerebrolysin studies cannot automatically establish the effectiveness of an oral 90 mg cerebroprotein hydrolysate tablet.
The Cochrane review of Cerebrolysin for acute ischemic stroke reviewed randomized trials of Cerebrolysin and did not find reliable evidence supporting its routine use for acute ischemic stroke. The review also raised concerns about non-fatal serious adverse events in some studies.
Other analyses have reached somewhat different conclusions. A 2025 meta-analysis of 14 randomized trials reported improvement in early neurological scores with Cerebrolysin but did not demonstrate a statistically significant improvement in functional independence; the authors concluded that further high-quality trials were needed to confirm long-term benefit.
An earlier meta-analysis similarly found no significant improvement in 90-day functional recovery compared with placebo.
These differences illustrate why strong claims such as “repairs the brain,” “speeds stroke recovery,” or “restores lost function” should be treated cautiously.
What Other Brain Health Uses Are Associated With Cogniza 90 mg?
Current Indian pharmacy references commonly list Cogniza for head injury and Alzheimer’s disease in addition to stroke. However, being marketed or prescribed for these conditions does not mean there is equally strong clinical evidence for every use.
Head injury and cognitive recovery
After traumatic brain injury, people may experience problems with attention, memory, speech, balance, behavior, or movement. A cerebroprotein preparation may be prescribed by some neurologists as supportive therapy.
Recovery from traumatic brain injury depends heavily on the location and severity of the injury, complications, rehabilitation, sleep, mental health, and other medical factors. Cogniza should not replace formal neurological assessment or rehabilitation when these are needed.
Memory and cognitive symptoms
Cogniza is also listed in India for Alzheimer’s disease. Cerebroprotein preparations have been investigated for possible effects on neuronal function, but product-specific clinical evidence for Cogniza 90 mg tablets is limited.
Laboratory and animal studies have reported neuroprotective effects with certain cerebroprotein hydrolysate preparations, but preclinical findings do not prove that the same treatment slows dementia in humans.
Someone developing progressive memory loss should therefore undergo proper assessment rather than starting Cogniza simply as a general “brain booster.” Memory problems can have many causes, including medication effects, depression, thyroid problems, vitamin deficiencies, sleep disorders, vascular disease, and neurodegenerative conditions.
What Benefits Can You Realistically Expect From Cogniza 90 mg?
Cogniza 90 mg is best viewed as a doctor-prescribed supportive neurological medicine rather than a treatment with guaranteed improvements in memory, movement, or independence. The amount of recovery after stroke or brain injury differs substantially between individuals.
A doctor may consider factors such as:
The type and severity of the neurological injury.
How long ago the stroke or injury occurred.
Current neurological symptoms.
Kidney function and seizure history.
Other medicines being taken.
Progress with rehabilitation.
Whether treatment appears to provide meaningful clinical benefit.
Improvement should be judged through function rather than vague ideas of “brain power.” Depending on the condition, meaningful outcomes might include better walking, greater independence in daily activities, improved speech, better attention, or measurable improvement on neurological or cognitive assessments.
You may not be able to tell whether Cogniza itself caused an improvement because recovery frequently occurs alongside rehabilitation and other treatments.
Do not increase the dose because recovery seems slow. Neurological rehabilitation usually occurs over weeks or months, and progress may be uneven.
What Matters Most Alongside Cogniza After a Stroke?
Structured rehabilitation and prevention of another stroke remain central to recovery. The 2026 American Heart Association/American Stroke Association guideline states that rehabilitation should involve sufficient amounts of task-specific practice and should address physical, cognitive, communication, mental-health, and participation needs.
Recovery plans may involve physiotherapists, occupational therapists, speech-language therapists, rehabilitation physicians, neurologists, nurses, psychologists, dietitians, and caregivers.
Secondary prevention is equally important. Depending on the cause of the stroke, this may involve management of blood pressure, cholesterol, diabetes, smoking, atrial fibrillation, weight, physical activity, and prescribed antiplatelet or anticoagulant medicines.
Dos and Don’ts When Cogniza 90 mg Is Used During Neurological Recovery
Do | Don’t |
Take Cogniza only in the dose and duration prescribed | Increase the dose hoping for faster brain recovery |
Continue prescribed rehabilitation exercises and therapy | Replace physiotherapy, speech therapy, or occupational therapy with the tablet |
Tell your doctor about seizures, kidney problems, pregnancy, breastfeeding, and other medicines | Assume a “brain health” medicine is automatically safe for everyone |
Track meaningful functional changes such as walking, speech, memory, and daily independence | Judge effectiveness only by feeling more energetic |
Continue medicines prescribed to prevent another stroke unless your doctor changes them | Stop antiplatelet, anticoagulant, blood-pressure, cholesterol, or other stroke medicines because Cogniza was added |
Seek immediate medical care for new stroke symptoms | Take extra Cogniza when sudden weakness, speech difficulty, or facial drooping appears |
What Are the Side Effects and Safety Precautions?
Cogniza 90 mg is a prescription medicine and should be used under medical supervision. Current Indian drug information advises caution in people with kidney problems or a history of seizures and recommends informing the doctor about pregnancy, plans for pregnancy, breastfeeding, and other medicines.
Reported symptoms associated with cerebroprotein hydrolysate products include headache, nausea, dizziness or vertigo, sweating, agitation, fever, confusion, and hallucinations. Not everyone develops these effects, and the frequency of specific reactions is not well established from high-quality product-specific studies.
Because CIMS describes Cogniza as a porcine brain-derived peptide product, people for whom animal origin is relevant should confirm the current formulation with their pharmacist or manufacturer before use.
Most importantly, do not use Cogniza to self-treat a possible new stroke. Sudden facial drooping, weakness or numbness on one side, new speech difficulty, loss of balance, sudden vision problems, or a severe unexplained neurological change requires emergency assessment. Acute stroke treatments are time-sensitive.
Conclusion
Cogniza 90 mg contains cerebroprotein hydrolysate and is marketed in India for neurological conditions including stroke, head injury, and Alzheimer’s disease. It may be prescribed as supportive therapy, but strong product-specific evidence proving that the oral tablet accelerates stroke recovery or improves long-term independence is limited. Research on related injectable peptide preparations has produced mixed results and should not be assumed to prove Cogniza’s effectiveness.
If Cogniza has been prescribed after a stroke, use it exactly as directed while continuing evidence-based rehabilitation and stroke-prevention treatment. Discuss expected benefits, treatment duration, seizure or kidney history, and any new symptoms with your neurologist.
Frequently Asked Questions
1. What is Cogniza 90 mg used for?
Cogniza 90 mg contains cerebroprotein hydrolysate and is listed in India for stroke, head injury, and Alzheimer’s disease. It is generally used as supportive neurological treatment. Its benefits should be considered alongside rehabilitation and other evidence-based care.
2. Does Cogniza 90 mg repair brain cells after a stroke?
It is marketed as a neuroprotective or nerve-supporting medicine, but saying it definitively “repairs brain cells” would overstate the evidence. Direct high-quality evidence for the Cogniza oral formulation is limited, and research on related injectable peptide products has produced mixed clinical results.
3. Can Cogniza improve memory?
Cogniza is sometimes prescribed for cognitive symptoms, but improvement is not guaranteed. Memory problems have many causes, and strong product-specific evidence that Cogniza 90 mg improves memory in all patients is lacking. Persistent or progressive memory problems should be medically assessed.
4. Is Cogniza enough for stroke recovery?
No. Stroke recovery usually requires multidisciplinary rehabilitation plus prevention of another stroke. The 2026 AHA/ASA guideline emphasizes physical, occupational, cognitive, communication, and other individualized rehabilitation strategies. Cogniza should not replace these treatments.
5. Can Cogniza 90 mg be taken if someone has epilepsy?
A current Indian medicine listing advises against or cautions about use in people with seizures or epilepsy. Tell the prescribing doctor about any seizure history before taking it and do not start or stop the medicine without medical guidance.
6. How long should Cogniza 90 mg be taken after a stroke?
There is no universal treatment duration that applies to everyone. The prescribing doctor should decide duration based on the reason for treatment, neurological recovery, other medical conditions, tolerability, and whether continued use appears appropriate. Do not extend the course independently.
Comments